Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term Arikace safety study in cystic fibrosis with chronic Pseudomonas aeruginosa infection
NL-OMON39469Phase 3Active, not recruiting
- Sponsor
- Chiltern International
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amikacin liposome inhalation suspension, sponsored by Chiltern International. Started May 2013; status: active, not recruiting.
02
Drugs
amikacin liposome inhalation suspension
Beyond the preview
Go deeper on NL-OMON39469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39469.